Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 11:30 a.m. EDT on Monday, September 22, 2008, at the UBS Global Life Sciences Conference in New York.

The update will include information about Geron’s portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1). The presentation will also include a review of the company’s human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1).

The audio only webcast will be available at the following website address: www.ibb.ubs.com. To access the webcast, click the “Conferences” icon in the center right of the page and follow the link for Webcast located next to the “Global Life Sciences” Conference heading. The replay will be available three hours after the live presentation until October 25, 2008.

Geron is a biopharmaceutical company that is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The products are based on our core expertise in telomerase and human embryonic stem cells. For more information, visit www.geron.com.

Contacts:

Geron Corporation
Anna Krassowska, 650-473-7765
Investor and Media Relations
info@geron.com